Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multiple Ascending Dose (MAD) Phase Ib/II Study of the mTOR Inhibitor (RAD001) in Combination With the IGF-1R Antagonist (R1507) for the Treatment of Patients With Advanced Solid Tumors

NCT00985374 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00985374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multiple Ascending Dose (MAD) Phase Ib/II Study of the mTOR Inhibitor (RAD001) in Combination With the IGF-1R Antagonist (R1507) for the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2009
Completion date
June 30, 2013
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms